Physical Education, Health and Social Sciences

https://journal-of-social-education.org E-ISSN: 2958-5996

P-ISSN: 2958-5988

A Review Article on Innovative Strategies for Thalassemia

Muhammad Taha Shahzad[1], Mohad Nazeer[2], Khadeeja Nasir[3]

[1,2] BS Department of Medical Laboratory Technology Superior University Lahore, mtahashahzad539@gmail.com, mahadnazir36@gmail.com

[3] Lecturer, Department of Medical Laboratory Technology Superior University Lahore, Corresponding Author, khadeeja.nasir@superior.edu.pk

DOI: https://doi.org/10.63163/jpehss.v3i2.269

Abstract

Thalassemia, a genetic blood disorder characterized by abnormal hemoglobin synthesis, poses a significant global health challenge. With a higher prevalence in the Mediterranean, Middle East, Asia, and parts of Africa, thalassemia has profound implications for affected individuals and healthcare systems. Public health initiatives, including awareness campaigns, genetic screening programs, and advancements in treatment, play a crucial role in mitigating the impact of this hereditary condition. However, economic disparities, inadequate healthcare infrastructure, and cultural barriers hinder effective management and prevention strategies. This study aims to explore the current state of thalassemia management, highlighting the obstacles to optimal care while recommending evidence-based public health strategies to enhance treatment outcomes and prevention measures. Public health initiatives addressing thalassemia encompass a range of strategies, including education campaigns, genetic screening, and improved access to treatment. Educational programs inform communities and healthcare professionals about the disorder, inheritance patterns, and the importance of genetic counseling. Additionally, specialized treatment centers and research collaborations enhance the accessibility and quality of care for thalassemia patients. Studies in various regions, including Cambodia, Pakistan, and other high-prevalence areas, indicate that while awareness and screening acceptance are increasing, gaps remain in healthcare accessibility and policy implementation. Despite advancements in thalassemia management, persistent challenges necessitate more comprehensive and inclusive public health strategies. Addressing socioeconomic disparities, improving healthcare infrastructure, and fostering culturally sensitive genetic counseling are essential for effective prevention and treatment.

Keywords: Thalassemia, Genetic Blood Disorder, PublicHealth Inatiatives, Genetic Screening, Awareness Campaigns, Treatment Accessibility, Prevention Strategies

Introduction

Thalassemia, a group of genetic blood disorders characterized by abnormal hemoglobin production, poses a significant global health challenge. As a hereditary condition, thalassemia affects millions of individuals worldwide, impacting their quality of life and placing a considerable burden on healthcare systems. In response to this pressing issue, public health initiatives have emerged as crucial components of a comprehensive strategy for thalassemia treatment and prevention. This comprehensive exploration aims to shed light on the various public health

initiatives implemented to address thalassemia, from awareness campaigns to screening programs and advanced treatment methods. By delving into the multifaceted aspects of thalassemia management, this article seeks to underscore the importance of public health efforts in mitigating the impact of this genetic disorder on individuals, families, and communities.[1] Before delving into the public health initiatives, it is essential to establish a foundational understanding of thalassemia. Thalassemia is a genetic disorder characterized by abnormalities in the synthesis of hemoglobin, the protein responsible for transporting oxygen in red blood cells. The severity of thalassemia varies, with individuals classified as carriers (thalassemia trait) experiencing mild symptoms, while those with the full-blown disorder may require lifelong medical intervention.[2] Thalassemia's impact is felt globally, with a higher prevalence in certain regions, such as the Mediterranean, Middle East, Asia, and parts of Africa. The global burden is compounded by the fact that carriers of the thalassemia gene may remain asymptomatic, unknowingly passing the genetic mutation to their offspring. As a result, effective public health strategies are vital in raising awareness, facilitating early detection, and providing appropriate care. Public health initiatives for thalassemia encompass a range of strategies, addressing prevention, early detection, and optimal management. These initiatives often begin with educational campaigns aimed at increasing awareness about thalassemia, its inheritance patterns, and the importance of genetic counseling. By disseminating information to communities and healthcare providers, these campaigns empower individuals to make informed decisions about family planning and genetic testing.[3] One cornerstone of thalassemia prevention is the implementation of genetic screening programs. These programs aim to identify carriers of thalassemia genes within populations, enabling early intervention and counseling. Prenatal screening for thalassemia has proven to be an effective tool in high-prevalence regions, allowing expectant parents to make informed choices about their pregnancy based on the genetic status of the fetus.[4] In addition to prenatal screening, many countries have instituted newborn screening programs to identify thalassemia carriers shortly after birth. Early detection through newborn screening allows for timely medical intervention and ongoing monitoring, ensuring that affected individuals receive the necessary care from infancy onward. This proactive approach significantly improves health outcomes and minimizes the impact of thalassemia-related complications. While screening programs play a pivotal role in prevention, ensuring access to affordable and effective treatment is equally crucial. Public health initiatives strive to enhance treatment accessibility, particularly in regions where resources may be limited. This involves the establishment of specialized thalassemia treatment centers, the training of healthcare professionals, and the implementation of supportive policies that facilitate affordable treatment options.[5] . Public health efforts are also closely linked to advancements in medical research. Ongoing research endeavors aim to discover new treatment modalities, gene therapies, and interventions that can further improve the quality of life for individuals with thalassemia. Public health initiatives play a key role in fostering collaboration between researchers, healthcare providers, and policymakers to ensure that emerging technologies are integrated into existing healthcare systems. Despite significant strides in thalassemia prevention and treatment, challenges persist. Economic disparities, inadequate healthcare infrastructure, and cultural stigmas surrounding genetic conditions continue to impede progress. Addressing these challenges requires a concerted effort from the global community, with a commitment to fostering inclusivity, equity, and cultural sensitivity in the implementation of public health initiatives. β- Thalassemia major is a hereditary condition resulting from a reduced or complete absence of β-globin chains, leading to microcytic hypochromic anemia [5]. Thalassemias are categorized into α and β types based on the affected globin chain. In β-Thalassemia major, there is a severe impairment in β-globulin synthesis, resulting in the formation of α-tetramers with unpaired alpha chains of hemoglobin. These α-

tetramers are highly insoluble and precipitate within erythrocytes, causing the cells to become fragile and undergo rapid breakdown, leading to ineffective erythropoiesis [6, 7]. β- thalassemia is associated with metabolic abnormalities, the accumulation of excessive iron in various organs, chronic hypoxia, and cellular injury. [8] Proper transfusion regimens help maintain a minimum hemoglobin level of 9-12 g/dL for up to 12 years in β-thalassemia major patients; however, a major complication of this treatment is iron overload, which can lead to organ dysfunction. [9] Iron initially accumulates in the bone marrow and subsequently in the liver and heart, becoming a key causative factor in conditions such as heart failure, cancer, renal, and nervous disorders. [10] Cardiac problems due to iron overload remain the primary cause of mortality in beta thalassemia patients. Thalassemia originated in Mediterranean regions as a result of hemoglobin's adaptation against the malarial parasite Plasmodium falciparum. Many developing countries, including Pakistan, are grappling with the threat of thalassemia. Treatment approaches vary between developed and developing countries due to differences in access to the latest techniques and facilities. Developed countries may employ advanced treatments such as bone marrow transplantation and gene therapy, which are not readily available in developing countries. Unfortunately, many β-thalassemicpatients in developing countries, especially children and adolescents, succumb to the lack of safe transfusions and chelation medication. [11]. In Pakistan, the carrier rate for thalassemia is estimated to be 5-7%, representing a carrier frequency of 9.8 million in the population. However, the lack of registration records for Pakistani patients poses a challenge in understanding the full extent of the issue. The assessment of hematological and biochemical parameters is crucial for evaluating the physical condition of thalassemic patients. In this study, we investigated the biochemical indices related to kidney, liver, and cardiac functioning. The findings aim to contribute to the prevention of serious damage to these vital organs, ultimately improving transfusion plans and chelation strategies for a better and longer life for individuals with β-thalassemia.

Literature Review

In a study in Cambodia in 2018, an intervention and control groups consisted of 124 and 117 individuals, aged 18 to 40, encompassing both males and females. Pre- and post-tests, utilizing a validated questionnaire, were administered to the intervention group, while the control group underwent a single test. A health education program was implemented to disseminate crucial information to the intervention group, with a similar session conducted for the control group at the conclusion of the study. Within the intervention group, 105 individuals (84.7%) expressed willingness to undergo blood screening, contrasting with 65 individuals (55.6%) in the control group. The mean scores for knowledge and attitude toward a prevention and control program for severe thalassemia in the intervention group exhibited a notable increase from 2.6 to 6.5 after the health education sessions. [12]. A comprehensive cross-sectional survey was carried out across the 36 districts of Punjab through the nine regional centers of the Punjab Thalassemia Prevention Project. The study involved interviewing 248 parents of individuals with Beta Thalassemia Major and Intermediary, utilizing a pre-designed and pre-tested structured questionnaire. Results indicated that 83.5% of the participants demonstrated sufficient knowledge, while an overwhelming 98.4% exhibited positive attitudes towards thalassemia prevention. Notably, there was a positive correlation observed between knowledge and attitude levels. A significant proportion, 93%, expressed a preference for prenatal diagnosis, and 91% were inclined towards the termination of an affected fetus. [13]. In the urban areas of Karachi, Pakistan, a cross-sectional descriptive study took place over six months, spanning from March 2016 to August 2016 with 720 samples. Through representative sampling, participants were chosen and interviewed face-to-face

using a pre-designed, pre-tested questionnaire. Surprisingly, only 53% of respondents were familiar with thalassemia. The average knowledge score stood at 5.8, with a possible range from 0 to 12, higher scores denoting better understanding. Interestingly, approximately three-quarters of the participants were unaware that an individual could be a carrier of thalassemia. Moreover, less than half of the sample believed in the necessity of premarital screening for thalassemia, and only 10% agreed that thalassemia carriers should abstain from marriage. Shockingly, 98% of families had not undergone any pre-marriage counseling. [14]. A cross-sectional study was conducted spanning four months, from May 2016 to August 2016, in the capital of Pakistan, Islamabad, and its adjacent city, Rawalpindi. Thalassemia treatment is available in both public and private sector hospitals in these cities. The final sample size, determined with 95% confidence limits, 5.5% precision, and considering a population size of registered thalassemia patients in Pakistan (100,000), was 317. Out of the 317 individuals invited to participate, 315 agreed, resulting in a response rate of 99.3%. Among the respondents, 90.8% were caregivers of thalassemia patients who had brought them to health facilities, while only 9.2% were patients themselves. The mean age of thalassemia major patients included in the study was 10.97 years, ranging from 5 to 31 years.[15]. In the urban areas of Karachi, Pakistan, a cross-sectional descriptive study took place over six months, spanning from March 2016 to August 2016 with 720 samples. Through representative sampling, participants were chosen and interviewed face-to-face using a pre-designed, pre-tested questionnaire. Surprisingly, only 53% of respondents were familiar with thalassemia. The average knowledge score stood at 5.8, with a possible range from 0 to 12, higher scores denoting better understanding. Interestingly, approximately three-quarters of the participants were unaware that an The research took place at two thalassemia centers in Multan, Pakistan: (i) The Children's Hospital & the Institute of Child Health and (ii) Fatimid Foundation, from March 20, 2019, to June 20, 2019. A total of 300 parents of thalassemia major patients were involved in the study. Data collection utilized a structured interview schedule with convenient sampling. Out of the 300 participants, the majority 201 were fathers, while 99 were mothers. A significant portion 177 hailed from rural areas, and the majority 153 had a primary level of education. The majority of respondents' family monthly income fell within the very low range of 5100-10000 PKR. Among the participants, 131 stated having 'no knowledge' of premarital screening and prenatal diagnosis, while 111 reported having some awareness. A large proportion 207 strongly agreed that thalassemia significantly impacted their financial situations. Overall, parents demonstrated inadequate awareness of premarital screening and prenatal diagnosis. [16]. Beta-thalassemia manifests in three primary forms: major, intermedia, and minor/silent carrier. Thalassemia major is the most severe, requiring regular blood transfusions for survival, leading to elevated iron levels and subsequent reactive oxygen species synthesis. This excess iron poses a threat to the liver, endocrine, and vascular systems. Diagnosis involves prenatal testing, blood smear analysis, complete blood count, and DNA analysis. While a thalassemia intermedium is managed symptomatically, folic supplementation and splenectomy can be employed as part of the treatment. [17]

In Lahore, a cross-sectional study was undertaken among biological parents of thalassemic children across three registered blood transfusion centers. Through systematic random sampling, 186 parents were chosen as the sample, and data was collected using a pretested questionnaire. The findings revealed that parents of registered thalassemic children exhibit sufficient knowledge regarding disease transmission and screening services. A notable 91% of participants correctly identified thalassemia major as a condition transmitted by parents, and 77% recognized cousin marriage as a potential source of transmission. Furthermore, 91% of parents were aware of prenatal screening, and 89% were knowledgeable about premarital screening. The study also highlighted

significant associations between parental knowledge and factors such as male gender, higher education, and income levels. [18]. In a descriptive cross-sectional study, 335 students from Punjab University and the University of Engineering and Technology, Lahore, were selected using convenient sampling. Thalassemia awareness and its correlation with carrier screening were evaluated through a modified questionnaire. Among the surveyed students, 54% exhibited a "Good" level of awareness about thalassemia, while 45.4% showed average knowledge, and a minimal 0.6% displayed poor understanding of the disease. In terms of thalassemia carrier screening, only 18% of students demonstrated a good knowledge level.[19]. A total of 55 individuals with thalassemia, along with their families, participated in the study after providing written consent. The research was conducted at the Department of Pathology and Diagnostic and Research Laboratory. Demographic details, including age, gender, education level, and family history of thalassemia, were documented, and statistical analysis was performed using SPSS 24.0. Among the 55 patients, the majority, comprising 33 individuals, were males, while 22 were females. The frequency of bimonthly blood transfusions was observed to be the lowest and 46 patients had parents who were in consanguineous marriages. Three siblings of thalassemia patients were diagnosed with thalassemia major, and seventeen siblings were found to have thalassemia minor. Additionally, thirty-five individuals exhibited a normal electrophoresis pattern. [20]

Fifty-four semi-structured qualitative interviews were carried out between April and June 2021, engaging with family members in seven cities across the Punjab province, namely Lahore, Sheikhupura, Nankana Sahab, Kasur, Gujranwala, Multan, and Faisalabad. Through thematic analysis, it was revealed that participants expressed contentment with both the content of the DeSIRe and its delivery by Family Outreach Workers (FOs) during family meetings. The participants comprehended that the primary goal of the DeSIRe was to enhance their understanding of β-thalassemia major (β-TM) and its hereditary aspects. This knowledge was intended to empower them to make informed decisions, particularly concerning thalassemia carrier testing, especially before entering into marriage. While concerns were raised about the potential stigma associated with testing positive, participants viewed the DeSIRe as a suitable intervention that facilitated informed decision-making among relatives.[21]. A purposeful sample of 142 survivors with thalassemia major was conveniently gathered from the primary center for thalassemia, Sundas Foundation, in Gujrat district, Punjab, Pakistan. The spatial locations of their home addresses were marked in a point shape file, and GIS technology along with spatial analysis techniques were employed for data analysis. ArcMap 10.3's Kernel Density Function was used to identify clusters of thalassemia patients in Gujrat district. The patient data indicates that 95% of cases were in the 05-20 age range. The study's results, based on incidence density and spatial maps, disclose that the major cluster of thalassemia patients is situated in Tehsil Gujrat. Additionally, fewer clusters of patients are observed in Tehsil Kharian and Sara-i-Alamgir. [22].

Objective

The main objectives of this study is

1. To initiate new public health programs for thalassemic patients
2. To speed awareness about the prevention of thalassemia

Material and Methods:

Thalassemia, a group of inherited blood disorders characterized by abnormal hemoglobin production, represents a major global health concern. Its genetic nature and wide-ranging impact on affected individuals, families, and communities necessitate effective public health strategies aimed at reducing the burden of the disorder. The disease's impact is compounded by the fact that

carriers of the thalassemia gene may be asymptomatic, thus posing a silent challenge to the broader population. Thalassemia, particularly β-thalassemia major, affects millions of people globally, with particularly high prevalence in regions such as the Mediterranean, Middle East, Asia, and parts of Africa. These areas have long experienced the effects of thalassemia, given the genetic adaptation of hemoglobin to malaria, especially in Mediterranean populations. However, the global challenge of thalassemia is exacerbated by the varying quality of healthcare available, the disparity in resources across regions, and the lack of public awareness regarding prevention, detection, and treatment.

Genetic Screening and Early Detection: Key Pillars of Prevention:

A critical step in the prevention of thalassemia lies in genetic screening programs, which are vital in identifying carriers of thalassemia and enabling early intervention. Genetic screening for thalassemia can occur at multiple stages, including premarital, prenatal, and newborn screening programs. These screening initiatives allow at-risk couples to make informed decisions about family planning, including genetic counseling. Prenatal screening, especially in high-prevalence regions, is an effective tool to determine the genetic status of the fetus, allowing parents to make decisions regarding pregnancy continuation or early management interventions. In countries where thalassemia is endemic, widespread awareness and education about genetic testing can dramatically reduce the birth rate of affected children.

Newborn screening, on the other hand, plays a pivotal role in early diagnosis. By identifying children with thalassemia early in life, healthcare providers can begin interventions such as regular blood transfusions, iron chelation therapy, and close monitoring to minimize complications associated with iron overload and other organ dysfunctions. For example, in countries like Greece, Cyprus, and Italy, newborn screening programs have significantly reduced the incidence of thalassemia major, contributing to improved health outcomes for individuals diagnosed with the disease.

Comprehensive Management: Addressing Treatment Gaps:

While prevention is a primary focus, comprehensive management of thalassemia requires a multifaceted approach. This includes access to appropriate medical care, transfusions, iron chelation therapies, and the development of specialized treatment centers. Blood transfusions are a cornerstone in the management of β-thalassemia major, as they help maintain hemoglobin levels and prevent complications of anemia. However, chronic transfusion therapy introduces a major concern: iron overload. As transfusions accumulate iron in the body, iron begins to deposit in vital organs, including the liver, heart, and kidneys, causing progressive organ damage. Iron overload is one of the leading causes of morbidity and mortality in thalassemia patients, especially those who do not have access to appropriate iron chelation therapies. Iron chelation therapy, which removes excess iron from the body, is an essential part of managing thalassemia. Effective iron chelation can help reduce the risk of organ damage and improve the quality of life for patients. However, accessibility to chelation medications remains a challenge, particularly in low-resource settings. In countries like Pakistan, where thalassemia prevalence is alarmingly high, the lack of access to advanced treatments such as bone marrow transplantation and gene therapy poses a significant barrier. In developed nations, patients may benefit from bone marrow transplants, which offer the possibility of a cure by replacing the patient's defective bone marrow with healthy marrow from a compatible donor. However, this treatment is expensive and not universally accessible, 15 particularly in developing countries. In regions where advanced treatments are unavailable, the focus is often on maintaining a rigorous transfusion regimen combined with iron

chelation therapy. Despite this, many patients in resource-limited settings do not receive the necessary level of care, leading to complications such as organ failure and premature death. Public health initiatives must continue to work towards making these treatments more widely available and accessible to all populations, particularly those in developing countries. This includes establishing specialized thalassemia treatment centers, improving healthcare infrastructure, and training healthcare professionals to manage the disorder effectively.

Emerging Research and Gene Therapy: A Glimmer of Hope:

Advancements in medical research and gene therapy offer hope for future treatment options. The development of gene editing technologies, such as CRISPR-Cas9, holds the potential to correct the genetic mutations responsible for thalassemia at a molecular level. In addition, stem cell research and gene therapy have demonstrated promise in clinical trials, with some patients experiencing long-term remission following gene therapy. These advances could revolutionize the treatment of thalassemia, providing a potential cure for individuals who currently rely on lifelong transfusions and chelation therapy. However, these therapies are still in the experimental stages and are not yet widely available. Furthermore, gene therapy treatments come with high costs, making them unaffordable for patients in many low-income countries. Public health systems must, therefore, not only support the ongoing development of these treatments but also work toward ensuring that their benefits can be shared equitably across all socioeconomic groups.

Addressing Challenges: Economic Disparities and Cultural Sensitivity:

Despite the potential benefits of medical advancements, significant challenges remain in tackling the global burden of thalassemia. Economic disparities and inadequate healthcare infrastructure continue to hinder progress, particularly in developing countries. In many regions, healthcare systems lack the necessary resources to provide consistent and comprehensive care to thalassemia patients. This is particularly evident in Pakistan, where the lack of registration records for thalassemia patients makes it difficult to assess the true scale of the issue. As a result, many individuals, particularly children and adolescents, face premature death due to insufficient medical care and limited access to transfusions and chelation therapy. Cultural factors also play a significant role in shaping the success of public health initiatives. In some regions, there is a stigma associated with genetic disorders, leading to reluctance in seeking genetic counseling or engaging with screening programs. Overcoming these cultural barriers requires sensitivity and community-based approaches to raise awareness about thalassemia, its genetic nature, and the importance of early detection and treatment. Public health campaigns that involve local communities in the design and delivery of education programs are more likely to be successful in overcoming resistance and fostering a culture of openness and support.

Conclusion:

Thalassemia remains a significant public health challenge worldwide, with a high prevalence in certain regions and a major impact on affected individuals and their families. Public health initiatives aimed at increasing awareness, facilitating early detection, and providing effective treatment are essential in mitigating the impact of the disorder. Genetic screening programs, newborn screening, and access to specialized treatment centers are critical components of the strategy to combat thalassemia. Furthermore, advances in medical research, including gene therapy, offer hope for a cure in the future. However, significant challenges remain, particularly in developing countries, where access to care and treatment is often limited. Addressing these challenges requires a coordinated effort from the global community, with a focus on equity,

inclusivity, and cultural sensitivity. Through comprehensive public health initiatives, the burden of thalassemia can be reduced, improving the quality of life for affected individuals and reducing the long-term social and economic impact of the disorder.

References

1. Weatherall, D.J., *The evolving spectrum of the epidemiology of thalassemia.* Hematology/Oncology Clinics, 2018. **32**(2): p. 165-175.
2. Taher, A.T., D.J. Weatherall, and M.D. Cappellini, *Thalassaemia.* The Lancet, 2018. **391**(10116): p. 155-167.
3. Musallam, K.M., et al., *Non-transfusion-dependent thalassemias.* haematologica, 2013. **98**(6): p. 833.
4. Modell, B. and M. Darlison, *Global epidemiology of haemoglobin disorders and derived service indicators.* Bulletin of the World Health Organization, 2008. **86**(6): p. 480-487.
5. Cao, A. and R. Galanello, *Beta-thalassemia.* Genetics in medicine, 2010. **12**(2): p. 61-76.
6. Gupta, K.K., A. Mishra, and A. Tiwari, *Production of reactive oxygen species, its effect, drugs and plant extract used as an antioxidant, chelator on thalassemic patient: a review.* International Journal of Pharmaceutical Sciences and Research, 2011. **2**(9): p. 2278.
7. Alavi, S., et al., *Hematological malignancies complicating β-thalassemia syndromes: a single center experience.* Blood Res, 2013. **48**(2): p. 149-151.
8. Saha, D. and A. Tamrakar, *Xenobiotics, Oxidative Stress, Free Radicals Vs. Antioxidants: Dance Of Death to Heaven's Life.* Asian Journal of Research in Pharmaceutical Science, 2011. **1**(2): p. 36-38.
9. Arshad, B., et al., *Hematological and biochemical changes in male patients with thalassemia major.* Pakistan J Life Soc Sci, 2014. **12**: p. 31-5.
10. Mansi, K., et al., *Biochemical factors relevant to kidney functions among Jordanian children with beta-thalassemia major treated with deferoxamine.* International Journal of Medicine and Medical Sciences, 2013. **5**(8): p. 374-379.
11. Alwan, A. and B. Modell, *Recommendations for introducing genetics services in developing countries.* Nature Reviews Genetics, 2003. **4**(1): p. 61-68.
12. Cheng, K., et al., *Effect of health education on severe thalassemia prevention and control in communities in Cambodia.* Archives of Public Health, 2018. **76**(1): p. 13.
13. Tariq, R., et al., *Impact Of Population Screening Programs On The Knowledge, Attitudes And Practices Regarding Prevention Of Thalassemia.* Pakistan BioMedical Journal, 2021. **4**(2): p. 209-214.
14. Ebrahim, S., et al., *Knowledge and Beliefs regarding thalassemia in an urban population.* Cureus, 2019. **11**(7)
15. Tanveer, T., H. Masud, and Z.A. Butt, *Are people getting quality thalassemia care in twin cities of Pakistan? A comparison with international standards.* International Journal for Quality in Health Care, 2018. **30**(3): p. 200-207.
16. Ishfaq, K., et al., *AWARENESS AMONG THE PARENTS OF CHILDREN WITH THALASSEMIA MAJOR, REGARDING PREMARITAL SCREENING AND PRENATAL DIAGNOSIS.*
17. Ali, S., et al., *Current status of beta-thalassemia and its treatment strategies.* Molecular Genetics & Genomic Medicine, 2021. **9**(12): p. e1788.
18. Manzoor, I. and R. Zakar, *Sociodemographic determinants associated with parental knowledge of screening services for thalassemia major in Lahore.* Pakistan Journal of Medical Sciences, 2019. **35**(2): p. 483.

19. Mushtaq, S., et al., *Thalassemia Awareness And Factors Associated With Carrier Screening Among Undergraduate Students In Lahore, Pakistan.* Central European Management Journal, 2023. **31**(4): p. 457-467.
20. Iqbal, R., et al., *Efficacy of Education in Providing Knowledge about Thalassemia Prevention and Family Screening of Thalassemic Patients.* Pakistan Journal of Medical & Health Sciences, 2023. **17**(06): p. 257-257.
21. Ahmed, S., et al., *Cascade screening for beta-thalassaemia in Pakistan: relatives' experiences of a decision support intervention in routine practice.* European Journal of Human Genetics, 2022. **30**(4): p. 406-412.
22. SIDDIQUI, S. and M.A.N. AKRAM, *SPATIAL ANALYSIS OF THALASSEMIA PATIENTS'PREVALENCE IN DISTRICT GUJRAT, PAKISTAN IN.*